改变滴定方案礼来降低其阿尔茨海默症抗体药物脑水肿发生率

2024年10月29日，礼来Eli Lilly宣布Donanemab（商品名：Kisunla）TRAILBLAZER-ALZ 6研究3b期临床试验取得积极结果。

发布时间：2024-10-29浏览数：29

FDA批准Donanemab用于治疗早期阿尔茨海默病

2024年7月2日，礼来公司宣布FDA批准Donanemab（商品名Kisunla™）350 mg/20 mL，每月一次静脉输注用于治疗处于轻度痴呆阶段，伴有轻度认知障碍（MCI），并经淀粉样蛋白病理学确诊的成人早期症状性…

发布时间：2024-07-02浏览数：248

Eli Lilly礼来公布抗Aβ单克隆抗体Donanemab的3期临床试验结果

2023年7月17日Eli Lilly公布了抗β淀粉样蛋白（Aβ）单克隆抗体Donanemab的3期临床试验TRAILBLAZER-ALZ 2试验结果。试验显示 Donanemab能够有效改善Aβ斑块检测阳性阿尔茨海默症早期症状患者的认…

发布时间：2023-07-17浏览数：792

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium t…

发布时间：2023-07-17浏览数：598

Donanemab in Early Alzheimer's Disease

In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76…

发布时间：2021-05-06浏览数：513

Donanemab (LY3002813) dose-escalation study in Alzheimer's disease

Intravenous donanemab 10 mg/kg can reduce amyloid deposits in AD despite having a shorter than expected half-life.

发布时间：2021-02-14浏览数：576

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice

These studies have profound implications for the development of therapeutic Aβ antibodies for Alzheimer's disease.

发布时间：2012-01-06浏览数：570

Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques

A beta N3(pE) production and retention may play an early and critical role in senile plaque formation.

发布时间：1995-02-01浏览数：509